Alexion to Present at the 14th Annual Citi Biotech Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Stifel Reiterates Hold Rating on Alexion Pharmaceuticals (ALXN)
August 30, 2019 12:14 PM EDTStifel analyst Paul Matteis reiterated a Hold rating and {REMOVEPT} price target on Alexion Pharmaceuticals (NASDAQ: ALXN)
The analyst comments "While the implications of a theoretical Soliris biosimilar launch (assuming ALXN converts) remain debatable, we expect the IPR institution decision this morning... More
Citi Is Buyer on Weakness in Alexion Pharmaceuticals (ALXN), Sees Fair Value around $131-$133
August 30, 2019 12:00 PM EDTCiti analyst Mohit Bansal reiterated a Buy rating and $150.00 price target on Alexion Pharmaceuticals (NASDAQ: ALXN).
Analyst is buyer on weakness.Sees FV around $131 to $133 per share.Says while weakness is justified, there is still value in the... More